Tanium Appoints Dan Streetman as Chief Executive Officer
1.2.2023 22:00:00 EET | Business Wire | Press release
Tanium, a leading IT operations and security management company and the premier supplier of converged endpoint management (XEM), today announced the appointment of Dan Streetman to the role of chief executive officer. Orion Hindawi, who is the co-founder and current CEO of Tanium, will assume the role of executive chairman. In this new role, Orion will continue to drive the strategic vision and technical innovation at Tanium as well as continue his engagement with Tanium’s strategic partners and customers. David Hindawi, co-founder of Tanium, will transition to chairman emeritus.
In his new role, Streetman will continue to strengthen Tanium’s commitment to protecting enterprises, organizations, and their people, while fortifying and evolving the company’s customer-facing operations, partner strategy, product strategy, and development.
Streetman will build on the strong market momentum that Tanium has seen, including coming off a record fiscal year in terms of revenue and new customer growth, impactful new product introductions, and the rapid adoption of Tanium’s converged endpoint management platform.
Streetman brings extensive and seasoned experience to Tanium. Most recently, he served as CEO of Allvue Systems; prior to that, he served as CEO of TIBCO Software Inc. In his earlier career, Streetman oversaw significant data-driven transformations at BMC, Salesforce, and C3.ai.
“Tanium is a mission-driven company whose commitment to serving customers’ needs is second to none,” said Streetman. “As digital transformation continues to create complexity and upend the cybersecurity landscape, organizations need a comprehensive endpoint management platform that protects their organizations and their people while helping them to break the point-product-proliferation cycle that has unfortunately left customers even less secure. It is an enormous opportunity to lead Tanium and am deeply committed to furthering its mission to provide certainty in uncertain times.”
“Founding and leading Tanium as its chief executive officer has been an honor, both personally and professionally,” said Orion Hindawi. “What started as an idea to help secure companies in the face of growing digital dependence and cyberattacks has blossomed into an endpoint management industry leader. Dan is a leader who shares our values, and I am proud that he is coming aboard to help write the next chapter of Tanium’s story. I have full confidence in his vision and his ability to responsibly nurture our organization’s growth.”
Today, with its converged endpoint management platform (XEM), Tanium is the premier vendor delivering real-time visibility, control, and remediation, all within a single platform. In addition, Tanium is expanding its platform capabilities to enable businesses to improve end-user productivity and provide a superior digital employee work experience. By bringing digital experience management capabilities into XEM, Tanium is poised to be an early leader in this new emerging market.
Streetman becomes the newest addition to an executive leadership team that possesses a wealth of experience, including Bina Chaurasia, chief administrative and operating officer; Charles Ross, chief customer officer; Marc Levine, chief financial officer; Nic Surpatanu, chief product officer; Steve Daheb, chief marketing officer; Tobias Julén, chief people officer; and Tyker Fagg, chief revenue officer.
About Tanium
Tanium, the industry’s only provider of converged endpoint management (XEM), leads the paradigm shift in legacy approaches to managing complex security and technology environments. Only Tanium unifies teams and workflows and protects every endpoint from cyber threats by integrating IT, Compliance, Security, and Risk into a single platform that delivers comprehensive visibility across devices, a unified set of controls, and a common taxonomy for a single shared purpose: to protect critical information and infrastructure at scale. Tanium has been named to the Forbes Cloud 100 list for seven consecutive years and ranks on Fortune’s list of the Best Large Workplaces in Technology. In fact, more than half of the Fortune 100 and the U.S. armed forces trust Tanium to protect people; defend data; secure systems; and see and control every endpoint, team, and workflow everywhere. That’s the power of certainty. Visit www.tanium.com and follow us on LinkedIn and Twitter.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230201005890/en/
Contact information
KC Higgins
Tanium PR
kc.higgins@tanium.com
+ 1 303.434.8163
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 12:47:00 EEST | Press release
Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food products. Within this inspiring premise, Good Food Makers confirms itself as one of the main levers f
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 11:16:00 EEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom